Click Here to Register »

Executive Sponsor

3M
Cambridge Consultants

Associate Sponsor

PharmaCircle

Technology Sponsors

Biocorp
Credence MedSystems
Enable Injections
Insulet Corporation
Lucideon
MedPharm
Novozymes
Renishaw
Salvona Technologies
Starpharma
Sensile Medical
Tergus
Unilife
Vectura

Supporting Sponsor

Team Consulting

Exhibitors

Beuhler Motor
Phillips-Medisize
Polysciences
Stress Engineering

Soapbox Sponsors

Bettinger
Pfizer
Portal Instruments

Media Partners

On Drug Delivery
Big3Bio
BioPharm Insight
BioPortfolio
Bloomberg Brief
Can Biotech
CenterWatch
Clinical Informatics News
Clocate.com
Drug Development & Delivery
Fierce Drug Delivery
HealthEconomics.Com
IPT
iptechex
Larta Institute
Life Science Leader
Massachusetts Life Sciences Center
MassBio
MCD Group
Medical News Today
Medtech Boston
OINDPnews
Pharmaphorum
PharmaVOICE
Technology Networks

Agenda

  • 8:00 am

  • Breakfast, Registration, Partnering Meetings

  • 8:45 am

  • Chair’s Opening Remarks

    Chair’s Opening Remarks

    Barbara Lueckel, PhD
    Head of Research & Technologies Partnering, Roche

  • 9:00 am

  • Opening Keynote Address on Nanotechnology

    Opening Keynote Address on Nanotechnology

    Robert Langer, PhD
    David H. Koch Institute Professor, MIT

  • 9:50 am

  • Industry Keynote

    We are delighted to welcome our 2015 industry keynote, Dr Bahija Jallal, EVP, MedImmune. Dr Jallal is responsible for biologics research, development and clinical activities. As part of AstraZeneca’s Senior Executive Team, she is tasked with advancing the biologic organization’s pipeline of drugs targeting cancer, infections, respiratory and inflammatory diseases, cardiovascular and gastrointestinal disorders and pain. Joining Dr Jallal on the stage is PODD veteran, Dr Anand Subramony, VP, Drug Delivery & Device Development, MedImmune.

    Bahija Jallal, PhD
    EVP, AstraZeneca, Head of MedImmune

    with

    Anand Subramony, PhD
    VP, Drug Delivery & Device Development, MedImmune

  • 10:30 am

  • Networking Break and Partnering Meetings

  • 11:15 am

  • Licensing Drug Delivery Technologies for Oncology Therapeutics

    In this panel, we will hear from business development and licensing executives regarding current level of interest in drug delivery technologies for pipeline and launched drugs.

    • Licensing improved formulations of off-patent cancer drugs vs. enabling platform technologies for NCEs
    • Criteria used to evaluate novel oncology drug delivery systems
    • What stage and type of data is most attractive to pharmaceutical partners?
    • Types of formulations and technology platforms actively sought:
      • Nanotechnology-based/Nanomedicine
      • Antibody drug conjugates
      • Sustained release depots/implants
    • Structuring partnerships – platform vs. product licenses, option-based agreements, regional deals

    Moderator:
    Barbara Lueckel, PhD
    Head of Research & Technologies Partnering, Roche

    Panelists:
    Vahe Bedian, PhD
    Director, Oncology External Projects, AstraZeneca

    Yalia Jayalakshmi (Jaya), PhD
    Senior Director, Drug Delivery Technologies, Onyx Pharmaceutical

    Philippe Lopes-Fernandes
    SVP, Head of Global Licensing & Business Development, Merck Serono / EMD Serono

    Neela Patel, PhD
    Director, Licensing-Search and Evaluation, Abbvie

    Denis Patrick, PhD
    Executive Director, Head External R&D Innovation, Oncology Research Unit, Pfizer

  • 12:00 pm

  • Sanofi Drug Delivery Case Study

    Paul Jansen
    VP, Medical Device Development, Sanofi

    Rob Veasey
    Senior Sector Manager, Medical and Scientific, DCA Design International

    Bill Welch
    Chief Technology Officer, Phillips-Medisize Corporation

  • 12:40 pm

  • A Year in Review in Drug Delivery: A PharmaCircle Perspective

    Tugrul Kararli, PhD, MBA
    President and Founder, PharmaCircle

  • 12:55 pm

  • Luncheon and Partnering Meetings

  • 2:15 pm

  • Drug Delivery Presentations in Three Tracks

    Track OneNon-Injectable Formulation Technologies
    Chaired by:
    Fernando Sallés, PhD
    VP, Head of Global Search, Teva Pharmaceuticals

    Track TwoInjectable Formulation Technologies
    Chaired by:
    Richard Korsmeyer, PhD
    Executive Director, Advanced External Projects, Pharmaceutical Sciences, Pfizer

    Track ThreeDrug Delivery Device Technologies
    Chaired by:
    Tomas Landh MSc, PhD
    VP, Innovation Sourcing, Novo Nordisk

    There will be a 15-minute break at 4:00 pm.

    If you are interested in presenting in one of the tracks, please contact Meredith Sands at Meredith@tcfllc.org.

  • 6:00 pm

  • Day One Concludes

Agenda

  • 8:00 am

  • Breakfast & Partnering Meetings

  • 8:45 am

  • CEO Keynote

    Stéphane Bancel joined Moderna in 2011 when it had one employee and patent and has assembled a company pioneering in the development of messenger RNA (mRNA) Therapeutics. It was recently named the #1 Disruptor on the third-annual CNBC Disruptor 50 list. For the second year in a row, CNBC recognizes Moderna as one of the country’s most ambitious and innovative companies changing the economy and overall business landscape.

    Stéphane Bancel
    CEO, Moderna Therapeutics

  • 8:30 am

  • Chair’s Welcome

    Chair’s Welcome

    Barbara Lueckel, PhD
    Head of Research & Technologies Partnering, Roche

  • 9:30 am

  • Utilizing Nanotechnology to Advance Targeted Therapies and Personalized Medicine

    Moderator:
    Omid Farokhzad, MD
    Associate Professor, Harvard Medical School

  • 10:15 am

  • Networking Break & Partnering Meetings

  • 11:00 am

  • Technology Spotlight

    Sponsored by:
    3M Drug Delivery Systems

  • 11:20 am

  • Large Volume Drug Delivery – Are Patch Pumps the Answer?

    Due to the increasing need for improved parenteral delivery of high dose pharmaceuticals, especially biologics, a number of new wearable devices have been developed, such as patch pumps and bolus injectors. These devices enable self-administration and eliminate the need for multiple injections or infusions. This panel will discuss the current generation of wearable injection devices and the opportunities and challenges that lie ahead.

    • Key drawbacks of current devices – what should next generation devices address?
    • Beyond insulin, will patch pumps be cost-effective for other drugs such as mAbs?
    • How does the size of the device affect patient acceptability?
    • Implementing acceptance of wearable technology
    • Selecting the appropriate device, and device manufacturer-partner

    Moderator:
    Christopher Coletta, PhD
    Director of Drug Delivery Strategy & Innovation, Amgen

    Panelists:
    Michael Graffeo
    VP, Business Development, Drug Delivery, Insulet Corporation

    David Haase
    Senior Manager, Device Development, Genentech

    Andrew Hamer, MD
    VP, Medical Affairs, Capricor Therapeutics

    Michael Hooven
    President and CEO, Enable Injections, LLC

    Anand Subramony
    VP, Drug Delivery & Device Development, MedImmune

    Speaker TBD
    Cambridge Consultants

  • 12:00 pm

  • Fifth Annual Company Spotlights

    In this session, we highlight three companies that discuss their partnering philosophy, current needs and scouting interests as related to drug delivery.

    Amgen
    Christopher Coletta, PhD
    Director of Drug Delivery Strategy & Innovation

    Sanofi-Genzyme BioVentures
    Ann DeWitt, PhD
    Senior Director of Investments

    Janssen
    Abla Creasey, PhD
    Senior Scientific Director, Pharmaceutical Development & Manufacturing Sciences

  • 1:00 pm

  • Luncheon and Partnering Meetings

  • 2:00 pm

  • Can RNA-based Therapeutics Really Deliver?

    Despite the therapeutic promise of RNA therapeutics, efficient and safe drug delivery remains a significant challenge. These therapeutics tend to have unfavorable physicochemical properties including negative charges, large molecular weight and size, and instability. A number of carrier systems are being developed for RNA therapeutics, including polymers, lipids, and conjugates, but selection of the delivery system depends on the therapeutics properties, type of target cells and the desired delivery route. This panel will discuss:

    • Key hurdles related to delivery of RNA therapeutics: siRNA, mRNA, RNAi
    • Delivery strategies and examples of recent successes
    • Collaborative approaches/models that are working
    • Commercialization prospects given low success rate of RNA drugs to-date

    Moderator:
    Jessica Ballinger
    Senior Director, Protein Pharmaceutical Development, Biogen Idec

    Panelists:
    Abla Creasey
    Senior Scientific Director, Pharmaceutical Development & Manufacturing Sciences, Janssen

    Jörg Kaufmann, PhD
    Chief Scientific Officer, Silence Therapeutics

    Muthiah (Mano) Manoharan, PhD
    Senior VP, Drug Discovery, Alnylam Pharmaceuticals

    Dave Rozema
    VP, Chemistry, Arrowhead Research

  • 2:45 pm

  • DDS Technology Soapbox@PODD sponsored by Pfizer

    Moderator:
    Christopher Bettinger, PhD
    Associate Professor, Carnegie Mellon University

    Julia Rashba-Step, PhD
    Senior Director, Novel Delivery Technologies, Pfizer BioTherapeutics

    This session features five-minute talks on cutting-edge technologies, inventions and ideas. The PODD Soapbox section is open to start-up entrepreneurs, inventors, licensing officers and university researchers.

    If you are interested in presenting on the Soapbox, please contact Meredith Sands at Meredith@tcfllc.org.

  • 3:45 pm

  • Improving Drug Delivery to the Back of the Eye

    There is an increasing need to successfully treat posterior eye diseases such as age-related macular degeneration, glaucoma, and diabetic retinopathy. Drug delivery to the back of the eye is challenging not only because of the anatomy of the eye and associated static and dynamic barriers, but also due to the growth of biologic therapeutics, and the challenges of delivering and stabilizing these more complex, large molecules. This panel will discuss goals and challenges of delivery, types of delivery systems showing promise for more effective delivery, and the benefits of collaborating in this space.

    Moderator:
    James Cunningham, PhD
    Director, Ocular Drug Delivery, Allergan

    Panelists:
    Ann Daugherty, PhD
    Senior Manager, Drug Delivery, Genentech

    Justin Hanes, PhD
    Lewis J. Ort Professor, Director, The Center for Nanomedicine at the Wilmer Eye Institute, Johns Hopkins University School of Medicine

    Viral Kansara, PhD
    Investigator and Lab Head – Ocular Pharmacology and Drug Delivery, Novartis

    Jaymin Shah, PhD
    Research Fellow, Pfizer